Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Stock Has Average Price Target of $46.43 According to Brokerages

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) has earned an average recommendation of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $46.43.

AAPG has been the subject of several research reports. BTIG Research reiterated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. B. Riley Financial started coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th.

Get Ascentage Pharma Group International alerts:

Check Out Our Latest Research Report on Ascentage Pharma Group International

Ascentage Pharma Group International Trading Down 2.4%

Shares of AAPG opened at $14.86 on Monday. Ascentage Pharma Group International has a 12-month low of $14.81 and a 12-month high of $40.47. The firm has a 50-day moving average price of $17.36 and a 200 day moving average price of $19.91. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. On average, sell-side analysts expect that Ascentage Pharma Group International will post -2.42 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.

See Also

• Five stocks we like better than Ascentage Pharma Group International
• Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
• Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
• Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
• Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.